Monash IVF Group (MVF) H1 2025 earnings summary

Executive summary

• Net profit after tax (NPAT) was AUD 17.3 million, with underlying NPAT up 5.5% to AUD 15.8 million, at the top end of guidance for 1H25.

• Revenue increased 11.6% to AUD 140.3 million, driven by price increases, acquisitions, and international growth.

• All business segments, including domestic ARS, ultrasound, and international, delivered robust revenue and earnings growth.

• Fully franked interim dividend increased to AUD 0.026 per share.

• Settlement of NiPGT class action and related insurance proceedings resulted in a net profit benefit in FY25.

Financial highlights

• Underlying EBITDA rose 10.7% to AUD 35.6 million; reported EBITDA up 29.4% to AUD 38.8 million, reflecting class action settlement proceeds.

• Underlying NPAT increased 5.5% to AUD 15.8 million; reported NPAT up 34.4% to AUD 17.3 million.

• EBITDA margin steady at 25%.

• Earnings per share increased to 4.4 cents from 3.3 cents year-over-year.

• Free cash flow was negative AUD 6.5 million, impacted by class action payments and capital expenditure.

Outlook and guidance

• Underlying group NPAT for FY25 is expected between AUD 30 million and AUD 31 million, slightly above the prior year.

• Short-term volatility in domestic ART sector expected to subside, with medium- to long-term growth supported by structural demand drivers.

• Non-regular FY25 items include new clinic commissioning, class action costs, and investment impairment.

• Volume growth for FY25 expected to be flat, with 2-3% market growth anticipated from FY26 onward.

• EBITDA margin improvement of 2% targeted by 2027, driven by cost optimization and technology investments.